CARIS LIFE SCIENCES established the Caris Centers of Excellence for Precision Medicine Network, appointing John Marshall as chairman.
THE PANCREATIC CANCER ACTION NETWORK and NCI's Frederick National Laboratory for Cancer Research will award two fellowships to support research on KRAS mutations that are relevant to pancreatic cancer.
SUE BIGGINS was awarded the Edward Novitski Prize by the Genetics Society of America.
A new study indicates that the risk of developing cancer in some types of tissue is based on the frequency of stem cell divisions, and therefore beyond individuals' control to minimize their own risks. As the study stated, a majority of these cancers develop due to random mutations of noncancerous stem cells; in other words, it's just “bad luck.”
The American Society of Clinical Oncologyannounced Jan. 21 that its CancerLinQ health information technology project will use the SAP HANA platform.
President Barack Obama called for innovation in genetic medicine, through the launch of a new initiative, in his State of the Union address Jan. 20.
The launch prices of anticancer drugs have increased substantially over time—even when adjusted for inflation and survival benefits—according to a study published by the National Bureau of Economic Research.
At first glance, it's hard to imagine anything as obscure as a policy by a private contracting firm that runs the Medicare program in the Carolinas, Virginia and West Virginia.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
Amgen ended all of its clinical studies of rilotumumab in advanced gastric cancer, including the phase III RILOMET-1 and RILOMET-2 trials.
